Importantly, HER3 has also been reported to be frequently overexpressed in breast cancer, and the activation of HER3 signaling was recently also reported to contribute to the resistance to HER2-targeted therapy [57,58,59,60]. The gene discussed is ERBB2; the disease is breast carcinoma.